IN VITRO EVALUATION OF ANTHELMINTIC ACTIVITY OF ETHANOLIC EXTRACT OF AERIAL PARTS OF PHYLLANTHUS FRATERNUSWEB. IN ADULT EARTHWORMS

Objective: The present study aimed to evaluate the anthelmintic activity of ethanolic extract of aerial part of Phyllanthus fraternus Web. leaves (EEPF) using adult earthworms (Pheretimaposthuma). Methods: Adult earthworms (24in number) were divided into 4 groups with 6 worms in each group (n=6). The anthelmintic activity of EEPF at two different doses (25 mg/ml and 50 mg/ml) were evaluated by assessing the time of paralysis (min) and time of death (min) of the earthworms. Albendazole (25 mg/ml) was used as standard and 2% gum acacia as control. Results: Data were analyzed statistically by ANOVA followed by Bonferroni test. P<0.05 was considered as significant. The result showed that EEPF had significant anthelmintic activity (p<0.001) but less potent than the standard drug albendazole. Conclusion: EEPF demonstrated significant anthelmintic activity but less potent than the standard drug albendazole. However, further studies with higher doses are required to evaluate the dose-dependent activity and to evaluate the exact mechanism responsible for anthelmintic activity

Hydrazone bimetallic complex: synthesis, characterization, in silico and biological evaluation targeting breast and lung cancer cells’ G-quadruplex DNA.

Manganese complex of (N'1E,N'3E)-N'1,N'3-bis(2-hydroxybenzylidene)isophthalo-hydrazide [H4L] was designed, spectroscopically analyzed, and confirmed via GC-MS, FTIR, CHNS, UV-VIS, magnetic susceptibility measurements, and molar electric conductivity. The data confirmed the formation of ligand H4L and [Mn2(H2L)Cl]Cl.2H2O complex. Ligand H4L acts as a bi-negative hexadentate and tetra-negative hexadentate coordinating through two amide carbonyl, two azomethine, and two deprotonated OH groups. The magnetic and spectral data proposed a squareplanar and a tetrahedral structure. The TGA data confirmed the final metal oxide form for the Mn ligand complex. Additionally, an in-vitro assessment of the ligand H4L confirmed its ability to control cancer cell proliferation in both breast (MCF7) and lung (A549) cancer cell lines while the Mn ligand complex possessed an anticancer effect in both cancer cells at the nano-molar level. Further, the in silico data showed four hydrogen bond interactions of the ligand with G-quadruplex DNA. This strengthens our hypothesis that the hydrazone complex acts as an anticancer agent by targeting the G-quadruplex DNA

Angiotensin receptors in GtoPdb v.2023.1

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [63, 155]), which have around 30% sequence similarity. The decapeptide angiotensin I, the octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. losartan, candesartan, olmesartan, telmisartan, etc. are clinically used AT1 receptor blockers

Angiotensin receptors in GtoPdb v.2025.3

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [63, 155]), which have around 30% sequence similarity. The octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. The "sartan" family drugs such as losartan, candesartan, olmesartan, telmisartan, etc. are clinically used AT1 receptor blockers

Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [61, 152]), which have around 30% sequence similarity. The decapeptide angiotensin I, the octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. losartan, candesartan, telmisartan, etc. are clinically used AT1 receptor blockers

Class A Orphans in GtoPdb v.2025.1

Table 1 lists a number of putative GPCRs identified by NC-IUPHAR [164], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail [124]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with as-yet unidentified endogenous ligands.Table 1: Class A orphan GPCRs with putative endogenous ligands GPR3GPR4GPR6GPR12GPR15GPR17GPR20 GPR22GPR26GPR31GPR34GPR35GPR37GPR39 GPR50GPR63GPR65GPR68GPR75GPR84GPR87 GPR88GPR132GPR149GPR161GPR183LGR4LGR5 LGR6MAS1MRGPRDMRGPRX1MRGPRX2P2RY10TAAR2 In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (GPR18, GPR55 and GPR119)

Class A Orphans in GtoPdb v.2023.1

Table 1 lists a number of putative GPCRs identified by NC-IUPHAR [161], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail [121]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with as-yet unidentified endogenous ligands.Table 1: Class A orphan GPCRs with putative endogenous ligands GPR3GPR4GPR6GPR12GPR15GPR17GPR20 GPR22GPR26GPR31GPR34GPR35GPR37GPR39 GPR50GPR63GPR65GPR68GPR75GPR84GPR87 GPR88GPR132GPR149GPR161GPR183LGR4LGR5 LGR6MAS1MRGPRDMRGPRX1MRGPRX2P2RY10TAAR2 In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (GPR18, GPR55 and GPR119)

Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database

Table 1 lists a number of putative GPCRs identified by NC-IUPHAR [194], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail [150]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with as-yet unidentified endogenous ligands.Table 1: Class A orphan GPCRs with putative endogenous ligands GPR3 GPR4 GPR6 GPR12 GPR15 GPR17 GPR20 GPR22 GPR26 GPR31 GPR34 GPR35 GPR37 GPR39 GPR50 GPR63 GRP65 GPR68 GPR75 GPR84 GPR87 GPR88 GPR132 GPR149 GPR161 GPR183 LGR4 LGR5 LGR6 MAS1 MRGPRD MRGPRX1 MRGPRX2 P2RY10 TAAR2 In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (GPR18, GPR55 and GPR119)